Similarly, the phase II ADAPT (Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer) trial revealed that early decrease in Ki-67 was correlated with increased pathologic complete response (pCR) to neoadjuvant treatment with either antibody-cytotoxic, anti-HER2 compound trastuzumab emtansine (T-DM1), or trastuzumab [214]. Here, MKI67 is linked to breast carcinoma.